Cargando…

Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2

The SARS-CoV-2 virus is currently the most serious challenge to global public health. Its emergence has severely disrupted the functioning of health services and the economic and social situation worldwide. Therefore, new diagnostic and therapeutic tools are urgently needed to allow for the early de...

Descripción completa

Detalles Bibliográficos
Autores principales: Wandtke, Tomasz, Wędrowska, Ewelina, Szczur, Marcin, Przybylski, Grzegorz, Libura, Marek, Kopiński, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836149/
https://www.ncbi.nlm.nih.gov/pubmed/35163338
http://dx.doi.org/10.3390/ijms23031412
_version_ 1784649606038028288
author Wandtke, Tomasz
Wędrowska, Ewelina
Szczur, Marcin
Przybylski, Grzegorz
Libura, Marek
Kopiński, Piotr
author_facet Wandtke, Tomasz
Wędrowska, Ewelina
Szczur, Marcin
Przybylski, Grzegorz
Libura, Marek
Kopiński, Piotr
author_sort Wandtke, Tomasz
collection PubMed
description The SARS-CoV-2 virus is currently the most serious challenge to global public health. Its emergence has severely disrupted the functioning of health services and the economic and social situation worldwide. Therefore, new diagnostic and therapeutic tools are urgently needed to allow for the early detection of the SARS-CoV-2 virus and appropriate treatment, which is crucial for the effective control of the COVID-19 disease. The ideal solution seems to be the use of aptamers—short fragments of nucleic acids, DNA or RNA—that can bind selected proteins with high specificity and affinity. They can be used in methods that base the reading of the test result on fluorescence phenomena, chemiluminescence, and electrochemical changes. Exploiting the properties of aptamers will enable the introduction of rapid, sensitive, specific, and low-cost tests for the routine diagnosis of SARS-CoV-2. Aptamers are excellent candidates for the development of point-of-care diagnostic devices and are potential therapeutic tools for the treatment of COVID-19. They can effectively block coronavirus activity in multiple fields by binding viral proteins and acting as carriers of therapeutic substances. In this review, we present recent developments in the design of various types of aptasensors to detect and treat the SARS-CoV-2 infection.
format Online
Article
Text
id pubmed-8836149
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88361492022-02-12 Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2 Wandtke, Tomasz Wędrowska, Ewelina Szczur, Marcin Przybylski, Grzegorz Libura, Marek Kopiński, Piotr Int J Mol Sci Review The SARS-CoV-2 virus is currently the most serious challenge to global public health. Its emergence has severely disrupted the functioning of health services and the economic and social situation worldwide. Therefore, new diagnostic and therapeutic tools are urgently needed to allow for the early detection of the SARS-CoV-2 virus and appropriate treatment, which is crucial for the effective control of the COVID-19 disease. The ideal solution seems to be the use of aptamers—short fragments of nucleic acids, DNA or RNA—that can bind selected proteins with high specificity and affinity. They can be used in methods that base the reading of the test result on fluorescence phenomena, chemiluminescence, and electrochemical changes. Exploiting the properties of aptamers will enable the introduction of rapid, sensitive, specific, and low-cost tests for the routine diagnosis of SARS-CoV-2. Aptamers are excellent candidates for the development of point-of-care diagnostic devices and are potential therapeutic tools for the treatment of COVID-19. They can effectively block coronavirus activity in multiple fields by binding viral proteins and acting as carriers of therapeutic substances. In this review, we present recent developments in the design of various types of aptasensors to detect and treat the SARS-CoV-2 infection. MDPI 2022-01-26 /pmc/articles/PMC8836149/ /pubmed/35163338 http://dx.doi.org/10.3390/ijms23031412 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wandtke, Tomasz
Wędrowska, Ewelina
Szczur, Marcin
Przybylski, Grzegorz
Libura, Marek
Kopiński, Piotr
Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2
title Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2
title_full Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2
title_fullStr Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2
title_full_unstemmed Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2
title_short Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2
title_sort aptamers—diagnostic and therapeutic solution in sars-cov-2
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836149/
https://www.ncbi.nlm.nih.gov/pubmed/35163338
http://dx.doi.org/10.3390/ijms23031412
work_keys_str_mv AT wandtketomasz aptamersdiagnosticandtherapeuticsolutioninsarscov2
AT wedrowskaewelina aptamersdiagnosticandtherapeuticsolutioninsarscov2
AT szczurmarcin aptamersdiagnosticandtherapeuticsolutioninsarscov2
AT przybylskigrzegorz aptamersdiagnosticandtherapeuticsolutioninsarscov2
AT liburamarek aptamersdiagnosticandtherapeuticsolutioninsarscov2
AT kopinskipiotr aptamersdiagnosticandtherapeuticsolutioninsarscov2